DHEA-S: What Your Number Changes About Your Treatment

What DHEA-S Actually Measures

DHEA-S is the sulfated storage form of DHEA, produced almost entirely by the zona reticularis of the adrenal cortex. Unlike cortisol, which pulses throughout the day, DHEA-S has a long half-life (10 to 20 hours) and stays relatively stable in circulation [1]. That stability makes it one of the most reliable single-draw markers of adrenal androgen function.

Why Clinicians Prefer DHEA-S Over DHEA

Free DHEA fluctuates with circadian rhythm and clears from the blood in minutes. DHEA-S, by contrast, circulates bound to albumin with negligible diurnal swing [2]. A morning blood draw and an afternoon blood draw will return nearly identical DHEA-S values. This consistency is why the Endocrine Society recommends DHEA-S (not free DHEA) as the initial screening analyte when adrenal androgen excess or deficiency is suspected [3].

The Biological Role

DHEA-S serves as a precursor pool. Peripheral tissues convert it into active androgens (testosterone, dihydrotestosterone) and estrogens (estradiol, estrone) through local enzymatic action [1]. The downstream conversion depends on tissue-specific expression of sulfatase, 3β-HSD, and aromatase enzymes. That means the same DHEA-S level can produce different hormonal effects in different people, which is exactly why your number matters for prescribing decisions.

Normal DHEA-S Ranges by Age and Sex

Reference ranges vary by laboratory assay, but major reference labs converge on similar age-stratified brackets. The values below reflect consensus ranges from the Endocrine Society and large reference laboratory data [3][4].

Women

| Age Range | DHEA-S (mcg/dL) | |-----------|-----------------| | 18-29 | 148-407 | | 30-39 | 98-340 | | 40-49 | 61-285 | | 50-59 | 35-256 | | 60-69 | 19-205 | | 70+ | 9-175 |

Men

| Age Range | DHEA-S (mcg/dL) | |-----------|-----------------| | 18-29 | 280-640 | | 30-39 | 210-510 | | 40-49 | 160-449 | | 50-59 | 110-370 | | 60-69 | 80-290 | | 70+ | 42-290 |

The Decline Curve

DHEA-S peaks in the mid-20s and drops roughly 2 to 3% per year after age 30. By age 70, most adults retain only 10 to 20% of their peak value [5]. This predictable decline is why age context is non-negotiable when interpreting results. A DHEA-S of 120 mcg/dL is unremarkable in a 65-year-old man. The same number in a 28-year-old man signals a problem.

What a High DHEA-S Means for Your Treatment

An elevated DHEA-S directs the clinical workup toward adrenal androgen excess. The differential diagnosis and prescribing response depend on the magnitude of elevation, the patient's sex, and the accompanying symptom profile.

Mild to Moderate Elevation in Women (PCOS Context)

In premenopausal women, DHEA-S between 200 and 600 mcg/dL alongside irregular cycles, acne, or hirsutism points toward polycystic ovary syndrome (PCOS). Roughly 20 to 30% of women with PCOS have isolated adrenal androgen excess with elevated DHEA-S as the primary marker [6]. The 2023 international evidence-based PCOS guideline recommends measuring DHEA-S when total testosterone alone does not explain the clinical picture [7].

Treatment shifts when DHEA-S is the driver. If a clinician was considering spironolactone for hirsutism based on elevated total testosterone, a co-elevated DHEA-S might prompt adding or substituting a low-dose glucocorticoid (dexamethasone 0.25 mg at bedtime) to suppress adrenal androgen output directly [3]. Combined oral contraceptives remain first-line for menstrual regulation, but the medication choice may tilt toward a formulation with stronger anti-androgenic progestin activity (drospirenone over levonorgestrel) when DHEA-S is high [7].

Marked Elevation (Above 600-700 mcg/dL)

DHEA-S values exceeding 600 to 700 mcg/dL in women or 800 mcg/dL in men warrant imaging to rule out an adrenal tumor [3]. Adrenal carcinomas can produce DHEA-S levels above 1,000 mcg/dL. This is one of the few scenarios where a single lab value triggers immediate diagnostic escalation. CT of the adrenal glands is the standard next step per Endocrine Society guidelines [8].

High DHEA-S and Existing Prescriptions

If you are already on testosterone replacement therapy (TRT) and your DHEA-S returns high, the clinician may reduce or pause exogenous DHEA supplementation. Stacking supplemental DHEA on top of high endogenous DHEA-S increases the risk of androgenic side effects (acne, oily skin, hair thinning) without added benefit [9]. High DHEA-S can also inflate calculated free testosterone, which may mask whether your TRT dose needs adjustment.

What a Low DHEA-S Means for Your Treatment

Low DHEA-S signals reduced adrenal androgen reserve. The clinical response depends on how low the value falls and what symptoms accompany it.

Adrenal Insufficiency Screening

A DHEA-S below the age-adjusted reference range, combined with fatigue, orthostatic hypotension, or unexplained weight loss, prompts evaluation for primary or secondary adrenal insufficiency. The Endocrine Society recommends a morning cortisol and ACTH stimulation test as the confirmatory workup [10]. DHEA-S alone does not diagnose adrenal insufficiency, but it raises the pre-test probability enough to justify the next step.

Age-Related Decline and Supplementation Decisions

For patients with DHEA-S levels in the bottom quartile for their age, clinicians may consider DHEA supplementation (typically 25 to 50 mg daily for women, 50 to 100 mg daily for men) [11]. The evidence base is mixed. A 2013 meta-analysis of 25 RCTs (N=1,353) found that oral DHEA supplementation raised serum DHEA-S and free testosterone but showed inconsistent effects on body composition, bone density, and sexual function in older adults [12].

Where DHEA supplementation has shown more consistent benefit is in women with adrenal insufficiency. A randomized trial (N=106) published in the New England Journal of Medicine found that 50 mg daily DHEA improved well-being scores, reduced depression and anxiety ratings, and increased serum androgen levels in women with primary and secondary adrenal insufficiency [13].

Low DHEA-S and HRT Adjustments

In perimenopausal and postmenopausal women on hormone replacement therapy, a low DHEA-S may prompt the addition of intravaginal DHEA (prasterone, brand name Intrarosa, 6.5 mg daily) for genitourinary syndrome of menopause. The FDA approved prasterone based on two phase III trials (N=813 combined) showing significant improvement in vaginal dryness, dyspareunia, and vaginal pH compared to placebo [14]. This specific formulation acts locally, converting to estrogens and androgens within vaginal tissue without meaningfully raising systemic hormone levels.

For women on systemic estradiol patches or oral estradiol, a persistently low DHEA-S despite adequate estrogen replacement may signal that androgen deficiency is contributing to residual fatigue, low libido, or cognitive fog. The International Menopause Society acknowledges that testosterone therapy (off-label) may be considered for postmenopausal women with low sexual desire, and DHEA-S is one of the supporting lab values used to build the clinical case [15].

How DHEA-S Shapes TRT and Testosterone Prescribing

DHEA-S is not the primary lab for initiating testosterone replacement. Total testosterone, free testosterone, LH, and FSH hold that role. But DHEA-S adds a layer of information that changes dosing strategy and monitoring.

Pre-TRT Baseline

Measuring DHEA-S before starting TRT establishes your adrenal androgen contribution. If pre-TRT DHEA-S is already high, total androgen load after adding exogenous testosterone may exceed the target range faster than expected [9]. Clinicians who skip this baseline sometimes overshoot the initial dose.

On-Treatment Monitoring

During TRT, DHEA-S helps distinguish adrenal androgen production from exogenous testosterone. If a patient on testosterone cypionate 100 mg weekly has a total testosterone of 1,100 ng/dL with DHEA-S of 450 mcg/dL, the adrenal glands are contributing meaningfully to the androgen pool. Dose reduction may be warranted even if the testosterone dose itself seems moderate [9].

Enclomiphene and DHEA-S

For men on enclomiphene (a selective estrogen receptor modulator used off-label to raise endogenous testosterone), DHEA-S provides a secondary check on adrenal androgen status. Enclomiphene stimulates LH and FSH at the pituitary but does not directly affect adrenal output [16]. If DHEA-S falls during enclomiphene therapy, the decline is unrelated to the medication and warrants independent evaluation.

How DHEA-S Interacts with Other Lab Results

DHEA-S rarely stands alone. Clinicians interpret it in panels alongside other markers. The combination determines the treatment path.

DHEA-S Plus Cortisol

High DHEA-S with normal cortisol suggests functional adrenal androgen excess (common in PCOS). High DHEA-S with high cortisol raises concern for Cushing syndrome or an adrenal adenoma and triggers a dexamethasone suppression test or 24-hour urinary free cortisol [8].

Low DHEA-S with low morning cortisol is the classic pattern of adrenal insufficiency. The Endocrine Society guideline on primary adrenal insufficiency recommends glucocorticoid replacement as first priority, with DHEA add-back considered for women who remain symptomatic despite adequate cortisol replacement [10].

DHEA-S Plus Testosterone and SHBG

DHEA-S, total testosterone, free testosterone, and sex hormone-binding globulin (SHBG) form the core androgen panel. When DHEA-S is low but total testosterone is normal, the gonads are compensating for poor adrenal output. This pattern may be unstable. If gonadal function also declines (as with aging), the patient can drop into frank androgen deficiency rapidly because there is no adrenal buffer.

When DHEA-S is high and SHBG is low, free androgen levels spike disproportionately. This combination is common in insulin-resistant patients and often accompanies a PCOS diagnosis in women or estrogen-deficient states in men [6].

DHEA-S Plus 17-Hydroxyprogesterone

If DHEA-S is elevated in a young woman with virilization symptoms, measuring 17-hydroxyprogesterone (17-OHP) helps differentiate PCOS from non-classic congenital adrenal hyperplasia (NCAH). An early-morning 17-OHP above 200 ng/dL warrants an ACTH stimulation test to confirm or exclude NCAH [3]. This distinction matters because NCAH is treated with low-dose hydrocortisone or dexamethasone rather than the anti-androgen and OCP approach used for PCOS.

How to Raise or Lower DHEA-S

Patients often ask whether they can change their DHEA-S through lifestyle or supplementation. The answer depends on the direction.

Raising Low DHEA-S

Oral DHEA supplementation (available over the counter in the US) is the most direct approach. Doses of 25 to 50 mg daily typically raise serum DHEA-S by 200 to 400% within 2 to 4 weeks [11]. Because DHEA converts to both androgens and estrogens, supplementation requires monitoring of testosterone, estradiol, and PSA (in men) at 6 to 8 week intervals until levels stabilize.

Exercise may modestly raise DHEA-S. A 2004 study (N=58) in the Journal of the American Geriatrics Society found that 6 months of resistance training increased DHEA-S by approximately 15% in older adults compared to sedentary controls [17]. The effect is small relative to supplementation but adds to the overall hormonal benefit of strength training.

Sleep quality also correlates with DHEA-S. Chronic sleep restriction suppresses adrenal androgen output. A study in the Journal of Clinical Endocrinology & Metabolism found that recovery sleep after experimental sleep debt partially restored DHEA-S levels in young adults [18].

Lowering High DHEA-S

Lowering DHEA-S pharmacologically is reserved for specific diagnoses. In PCOS with adrenal androgen excess, low-dose dexamethasone (0.25 to 0.5 mg nightly) suppresses ACTH-driven DHEA-S production by 40 to 60% [3]. This approach carries long-term glucocorticoid risks and is not used casually.

Metformin, commonly prescribed in PCOS for insulin resistance, may indirectly lower DHEA-S by improving insulin sensitivity. A 2009 randomized trial (N=100) showed that metformin 1,500 mg daily reduced DHEA-S by 18% over 6 months in women with PCOS compared to placebo [19]. The effect is moderate, and metformin is rarely prescribed solely to lower DHEA-S.

Weight loss in overweight patients with PCOS reduces adrenal androgen output. A 5 to 10% reduction in body weight has been associated with meaningful DHEA-S decreases in multiple observational studies [7].

When and How Often to Test DHEA-S

DHEA-S does not belong on every routine lab panel. Targeted ordering improves clinical value.

Indications for Initial Testing

The Endocrine Society and AACE recommend DHEA-S testing in the following scenarios: evaluation of hirsutism or virilization in women, workup of suspected adrenal insufficiency, assessment of adrenal androgen status before starting hormone therapy, and evaluation of premature adrenarche in children [3][10]. The USPSTF does not recommend population-level screening for DHEA-S in asymptomatic adults.

Monitoring Frequency

For patients on DHEA supplementation, check DHEA-S at baseline, 6 to 8 weeks after initiation, and every 6 to 12 months thereafter [11]. For patients on TRT, annual DHEA-S measurement is reasonable as part of the comprehensive hormone panel. For PCOS patients on treatment, DHEA-S every 6 months helps track whether adrenal suppression therapy is working.

No fasting is required. No specific time-of-day restriction applies, though morning draws are conventional for consistency with cortisol co-testing [2].

The Clinical Bottom Line

Your DHEA-S result is not decorative. It changes whether your clinician starts DHEA supplementation, adjusts your TRT dose, investigates your adrenal glands, or shifts your PCOS management from ovarian-focused to adrenal-focused therapy. A 28-year-old woman with a DHEA-S of 525 mcg/dL and hirsutism gets a different prescription than one with a DHEA-S of 110 mcg/dL and the same symptoms. The number dictates the path.

For women with adrenal insufficiency, 50 mg daily oral DHEA raised well-being scores by 11 points on the SCL-90 scale and reduced Beck Depression Inventory scores by 4.5 points over 4 months in the Arlt et al. NEJM trial (N=24 in the crossover analysis) [13]. That specific, measurable benefit only applies if DHEA-S is genuinely low. Testing confirms whether the intervention fits.